





Correction

Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. *Cancers* 2020, 12, 2447

Gil Bar-Sela ^{1,2,*}, Idan Cohen ¹ , Salvatore Campisi-Pinto ³, Gil M. Lewitus ³ , Lanuel Oz-Ari ², Ayellet Jehassi ⁴, Avivit Peer ⁵, Ilit Turgeman ⁵ , Olga Vernicova ¹, Paula Berman ³ , Mira Wollner ⁵, Mor Moskovitz ⁵ and David Meiri ^{3,*}

- ¹ Cancer Center, Emek Medical Center, 21 Yitzhak Rabin Blvd, Afula 1834111, Israel; idan5161@gmail.com (I.C.); olga_vr@clalit.org.il (O.V.)
 - ² Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 320002, Israel; lanuel.fuchs@gmail.com
 - ³ The Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, Haifa 320003, Israel; campisi.pinto@gmail.com (S.C.-P.); lgil@technion.ac.il (G.M.L.); bermansh@gmail.com (P.B.)
 - ⁴ Statistic Unit, Emek Medical Center, Afula 1834111, Israel; ayelletaj@gmail.com
 - ⁵ Division of Oncology, Rambam Health Care Campus, Haifa 320002, Israel; a_peer@rambam.health.gov.il (A.P.); i_turgeman@rambam.health.gov.il (I.T.); m_wollner@rambam.health.gov.il (M.W.); m_moskovitz@rambam.health.gov.il (M.M.)
- * Correspondence: gil_ba@clalit.org.il (G.B.-S.); dmeiri@technion.ac.il (D.M.); Tel.: +972-4-6495723 (G.-B.S.); +972-77-8871680 (D.M.); Fax: +972-4-8135805 (G.B.-S.); +972-77-8871680 (D.M.)



Citation: Bar-Sela, G.; Cohen, I.; Campisi-Pinto, S.; Lewitus, G.M.; Oz-Ari, L.; Jehassi, A.; Peer, A.; Turgeman, I.; Vernicova, O.; Berman, P.; et al. Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. *Cancers* 2020, 12, 2447. *Cancers* 2022, 14, 1957. <https://doi.org/10.3390/cancers14081957>

Received: 22 March 2022

Accepted: 8 April 2022

Published: 13 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Error in Table

In the original article [1], there was a mistake in Table 1 as published. Typing errors were made regarding demographics and medical conditions data. The corrected Table 1 appears below.

Table 1. Demographics and medical conditions.

Characteristics	Cannabis Non-Users N = 68	Cannabis Users N = 34	p-Value
Age in years median (range)	69 (18–92)	66 (37–85)	
Gender—N (%)			
Female	22 (32.4)	10 (29.5)	
Male	46 (67.6)	24 (70.5)	0.9399
Performance Status Eastern Cooperative Oncology Group (ECOG)—N (%)			
1 <	55 (80.8)	24 (70.5)	0.3568
≥2	13 (19.1)	10 (29.4)	0.3568
Chronic diseases per patient—N (%)			
0	22 (32.3)	13 (22.0)	0.7124
1	16 (23.5)	7 (20.5)	0.9332
2 or more	30 (44.1)	14 (41.1)	0.9437
Background diseases—N (%)			
Chronic heart disease	18 (26.4)	5 (14.7)	0.2762
Diabetes	17 (25.0)	6 (17.6)	0.5576
High blood pressure	34 (50.0)	13 (34.1)	0.3612
Chronic obstructive pulmonary disease (COPD)	9 (13.2)	3 (8.8)	1
Hyperlipidemia	23 (33.8)	7 (20.5)	0.2491
Other	2 (2.9)	0 (0.0)	1
Type of malignancy—N (%)			
Non-small cell lung cancer	37 (54.4)	20 (58.8)	0.8325
Melanoma	25 (36.7)	9 (26.4)	0.414
Renal cell carcinoma	4 (5.8)	2 (5.8)	1
Other	2 (2.9)	3 (8.8)	1
Main site of metastasis—N (%)			
Brain	12 (17.6)	8 (13.2)	0.6593
Lungs	39 (57.3)	23 (67.6)	0.4303
Liver	13 (19.1)	11 (32.3)	0.2157

Table 1. *Cont.*

Characteristics	Cannabis Non-Users N = 68	Cannabis Users N = 34	p-Value
Immunotherapy given as—N (%)			
First line of treatment	31 (45.5)	8 (23.5)	0.05178
Second line of treatment or more	37 (54.4)	26 (76.4)	0.05178
Checkpoint therapy—N (%)			
Anti PD1: Pembrolizumab or Nivolumab	47 (69.1)	29 (85.2)	0.127
Ipilimumab and Nivolumab	16 (23.5)	4 (11.7)	0.2517
Anti PDL-1: Durvalumab or Atezolizumab	5 (7.3)	1 (2.9)	1

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

1. Bar-Sela, G.; Cohen, I.; Campisi-Pinto, S.; Lewitus, G.M.; Oz-Ari, L.; Jehassi, A.; Peer, A.; Turgeman, I.; Vernicova, O.; Berman, P.; et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. *Cancers* **2020**, *12*, 2447. [[CrossRef](#)] [[PubMed](#)]